( shares reached a new low for the 52-week period during Monday's trading. The stock traded as low at $10.39, and as recently as $10.54. A total of 5680 shares were traded. Stock had closed previously at $10.53.
Evotec Stock Performance
The company has a $3.48 billion market cap, a 25.68 price-to earnings ratio and a beta value of 0.98. The stock's 200-day moving average is $8.24 and its 50-day moving average $9.84. The company's current ratio is 2.57, its quick ratio is 2.50, and it has a debt to equity ratio of 0.53
Evotec Company profile
Evotec SE is engaged in the development and discovery of new drugs by pharmaceutical and biotechnology firms. It is divided into two segments: EVT Innovate and EVT Execute. The EVT Execute Segment provides integrated or stand-alone drug discovery solutions to collaborators, targets, and programmers. These are provided on a fee-for service basis, or via a variety commercial structures that may include performance-based elements, such as milestones, and royalties.
MarketBeat.com offers a FREE daily email newsletter